Treatment of sarcoidosis using placental stem cells

A technology of placental stem cells and sarcoidosis, applied in metabolic diseases, skin diseases, sensory diseases, etc., can solve problems such as limitations

A technology of placental stem cells and sarcoidosis, applied in metabolic diseases, skin diseases, sensory diseases, etc., can solve problems such as limitations

CN102933221AInactive Publication Date: 2013-02-13ANTHROGENESIS CORP
18 Cites 0 Cited by

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of sarcoidosis using placental stem cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 2

[0361] 5.2 Example 2: Using Placental Stem Cells to Treat Cardiac Sarcoidosis

[0362] Subjects present with shortness of breath, swelling of the legs and ankles, and an irregular heartbeat. After exclusion of other causes and a confirmatory ECG, a diagnosis of cardiac sarcoidosis was made. After the individual was stabilized with nitroglycerin and streptokinase, the individual was given 1x10 in 0.9% saline 8 ~5x10 8 CD10 + , CD34 - , CD105 + 、CD200 + For PDACs, inject directly into the affected site under local anesthesia using a cardiac syringe. The individual is monitored on an emergency basis for the next 72 hours. During the three months following treatment, the individual was further monitored by electrocardiogram and / or dye visualization techniques. Treatment effectiveness is determined if any of the above symptoms improve during the monitoring period.

Embodiment 3

[0363] 5.3 Example 3: Treatment of Cutaneous Sarcoidosis Using Placental Stem Cells

[0364] Subject presents with complaints of nodules occurring on both lower legs. A scratch biopsy was performed, and histological examination revealed granulomatous inflammation with polarizable foreign material. After excluding other causes, a diagnosis of cutaneous sarcoidosis was made. Give the individual 1x10 in 0.9% saline 8 ~5x10 8 CD10 + , CD34 – , CD105 + 、CD200 + PDACs, administered directly to the skin lesion. Over the next three months, the individual is monitored for changes in skin nodules. Treatment effectiveness is determined for that individual if any of these signs show improvement during the monitoring period.

[0365] 5.4 Example 4: Using placental stem cells to treat neurosarcoidosis

[0366] A 50-year-old individual presented with leg numbness and muscle weakness. Imaging methods revealed irregularly contoured and mass-like lesions in the spinal cord. Biopsy ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided herein are compositions and methods of treating individuals having sarcoidosis or a sarcoidosis-related disease or disorder, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein. Also provided herein are kits comprising said cells or a composition thereof.

Description

1. Field of invention [0001] Provided herein are isolated placental cells (e.g., placental stem cells), populations of such placental stem cells, and their use in the treatment of sarcoidosis or sarcoidosis-related diseases, disorders or conditions such as systemic sarcoidosis, skin nodules festival disease, Syndrome, neurosarcoidosis, pulmonary sarcoidosis, cardiac sarcoidosis, ocular sarcoidosis, or sarcoidosis with other organ or tissue involvement. 2. Background of the invention [0002] Sarcoidosis, also known as sarcoid disease or Besnier-Boeck disease, is a multisystem granulomatous inflammatory disease that can affect multiple organs (eg, lungs, skin, heart, eyes, liver, nervous system, kidney or musculoskeletal system). The etiology of sarcoidosis remains unclear, although it has been thought to be related to altered immune responses in genetically susceptible individuals following exposure to environmental, occupational, or infectious agents. [0003] Steroid t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
13 Feb 2013
Publication
CN102933221A
IPC
A61K35/50
CPC
A61K35/50; A61K45/06; A61P1/14; A61P11/00; A61P11/02; A61P11/14; A61P17/00; A61P17/02
Inventors
詹姆士·爱丁格; 史蒂芬·菲施科夫